By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutical Inc.  

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560  U.S.A.
Phone: 609-730-2000 Fax: n/a



Company News
Protagonist (PTGX) Announces Closing Of Janssen Pharmaceutical License And Collaboration Agreement For PTG-200 And Receipt Of $50 Million Payment 8/25/2017 6:45:56 AM
Bavarian Nordic (BAVA.CO) Announces Closing Of Transaction With Janssen Pharmaceutical And Issue Of Shares To Johnson & Johnson Innovation (JNJ) - JJDC 8/22/2017 10:26:13 AM
Janssen Pharmaceutical Release: New XARELTO (Rivaroxaban) Data At ESC Congress 2017 Includes Late-Breaking Results From Landmark Phase III COMPASS Study 8/21/2017 7:10:18 AM
Janssen Pharmaceutical Release: Pimodivir Alone Or In Combination With Oseltamivir Demonstrated A Significant Reduction In Viral Load In Adults With Influenza A 6/14/2017 7:04:18 AM
Janssen Pharmaceutical Release: New Phase III Data Show Anti-TNF Alpha SIMPONI ARIA (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis 6/14/2017 6:28:54 AM
Janssen Pharmaceutical Release: INVOKANA (canagliflozin) Significantly Reduces The Combined Risk Of Cardiovascular Death, Myocardial Infarction And Stroke In The CANVAS Program 6/13/2017 6:40:51 AM
Janssen Pharmaceutical Announces Submissions In Europe And U.S. For Single-Tablet Regimen Of Dolutegravir Plus Rilpivirine - The First Two-Drug HIV Maintenance Treatment 6/2/2017 6:31:08 AM
Janssen Pharmaceutical Release: Real-World Evidence Shows Oral INVOKANA 300 Mg Demonstrates Comparable A1C Reduction And Control To Injectable GLP-1 Receptor Agonists 5/8/2017 6:35:30 AM
Janssen Pharmaceutical Announces HealtheVoices Impact Fund 4/25/2017 9:41:00 AM
Janssen Pharmaceutical Collaborates With Premier, Inc. On Unique Study To Improve Stroke Risk Management Among Hospitalized Patients With Atrial Fibrillation 4/3/2017 9:09:06 AM